These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 2623427)
1. Cell-mediated and humoral immune responses to BCG and rubella vaccinations and to recall antigens in onchocerciasis patients. Kilian HD; Nielsen G Trop Med Parasitol; 1989 Dec; 40(4):445-53. PubMed ID: 2623427 [TBL] [Abstract][Full Text] [Related]
2. Cell-mediated and humoral immune response to tetanus vaccinations in onchocerciasis patients. Kilian HD; Nielsen G Trop Med Parasitol; 1989 Sep; 40(3):285-91. PubMed ID: 2617034 [TBL] [Abstract][Full Text] [Related]
3. [Evaluation of the specific immune response after anti-rubella vaccination]. Cellesi C; Rossolini A; Rossolini GM; Bianchi Bandinelli ML; Cusi MG; Egisto Valensin P Quad Sclavo Diagn; 1988; 24(1-4):97-105. PubMed ID: 3268925 [TBL] [Abstract][Full Text] [Related]
4. Guatemalan human onchocerciasis. II. Evidence for IgG3 involvement in acquired immunity to Onchocerca volvulus and identification of possible immune-associated antigens. Boyer AE; Tsang VC; Eberhard ML; Zea-Flores G; Hightower A; Pilcher JB; Zea-Flores R; Zhou W; Reimer CB J Immunol; 1991 Jun; 146(11):4001-10. PubMed ID: 2033268 [TBL] [Abstract][Full Text] [Related]
5. Humoral immunogenicity to measles, rubella, and varicella-zoster vaccines in biliary atresia children. Wu JF; Ni YH; Chen HL; Hsu HY; Lai HS; Chang MH Vaccine; 2009 May; 27(21):2812-5. PubMed ID: 19366583 [TBL] [Abstract][Full Text] [Related]
6. Impaired tetanus-specific cellular and humoral responses following tetanus vaccination in human onchocerciasis: a possible role for interleukin-10. Cooper PJ; Espinel I; Paredes W; Guderian RH; Nutman TB J Infect Dis; 1998 Oct; 178(4):1133-8. PubMed ID: 9806045 [TBL] [Abstract][Full Text] [Related]
7. Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines. Nordøy T; Husebekk A; Aaberge IS; Jenum PA; Samdal HH; Flugsrud LB; Kristoffersen AC; Holte H; Kvaløy S; Kolstad A Bone Marrow Transplant; 2001 Oct; 28(7):681-7. PubMed ID: 11704791 [TBL] [Abstract][Full Text] [Related]
8. Tuberculin skin tests and B.C.G. vaccination in hyperendemic area of onchocerciasis. Rougemont A; Boisson-Pontal ME; Pontal PG; Gridel F; Sangare S Lancet; 1977 Feb; 1(8006):309. PubMed ID: 64835 [No Abstract] [Full Text] [Related]
9. Delayed-type hypersensitivity reactions to Onchocerca volvulus antigens in exposed and non-exposed African individuals. Burchard GD; Brattig NW; Kruppa TF; Horstmann RD Trans R Soc Trop Med Hyg; 1999; 93(1):103-5. PubMed ID: 10492804 [TBL] [Abstract][Full Text] [Related]
10. [Immune response of rubella vaccine in the populations with different age groups]. Xiong XW; Diao LD; Yan XL Zhonghua Liu Xing Bing Xue Za Zhi; 1997 Aug; 18(4):227-9. PubMed ID: 9812525 [TBL] [Abstract][Full Text] [Related]
11. Immunological studies on onchocerciasis in Sierra Leone. 1. Pretreatment baseline data. Luty AJ; Downham MD; Whitworth JA; Morgan D; McNicholas A; Taylor DW Trop Med Parasitol; 1990 Dec; 41(4):371-5. PubMed ID: 2075381 [TBL] [Abstract][Full Text] [Related]
12. Postinfection and postvaccination antirubella immunity. Kańtoch M; Imbs D Acta Virol; 1986 Sep; 30(5):381-9. PubMed ID: 2878585 [TBL] [Abstract][Full Text] [Related]
13. Onchocerca volvulus: a comparative study of in vitro neutrophil killing of microfilariae and humoral responses in infected and endemic normals. Johnson EH; Lustigman S; Kass PH; Irvine M; Browne J; Prince AM Exp Parasitol; 1995 Aug; 81(1):9-19. PubMed ID: 7628571 [TBL] [Abstract][Full Text] [Related]
14. Ivermectin-facilitated immunity in onchocerciasis. Reversal of lymphocytopenia, cellular anergy and deficient cytokine production after single treatment. Soboslay PT; Dreweck CM; Hoffmann WH; Lüder CG; Heuschkel C; Görgen H; Banla M; Schulz-Key H Clin Exp Immunol; 1992 Sep; 89(3):407-13. PubMed ID: 1516257 [TBL] [Abstract][Full Text] [Related]
15. The prevalence of epilepsy follows the distribution of onchocerciasis in a west Ugandan focus. Kaiser C; Kipp W; Asaba G; Mugisa C; Kabagambe G; Rating D; Leichsenring M Bull World Health Organ; 1996; 74(4):361-7. PubMed ID: 8823957 [TBL] [Abstract][Full Text] [Related]
16. [The evaluation of endemic onchocerciasis in the Amou prefecture (Togo)]. Dogba PK; Komi BT Bull Soc Pathol Exot; 1994; 87(2):110-1. PubMed ID: 8061527 [TBL] [Abstract][Full Text] [Related]
17. Comparative studies of clinical groups of patients in an onchocerciasis endemic area for evidence of immune-mediated protection. Ngu JL; Tume C; Lando G; Ndumbe P; Leke RG; Titanji V; Asonganyi T Trop Med Parasitol; 1989 Dec; 40(4):460-3. PubMed ID: 2623428 [TBL] [Abstract][Full Text] [Related]
18. The contribution of HLA class I antigens in immune status following two doses of rubella vaccination. Ovsyannikova IG; Jacobson RM; Vierkant RA; Jacobsen SJ; Pankratz VS; Poland GA Hum Immunol; 2004 Dec; 65(12):1506-15. PubMed ID: 15603879 [TBL] [Abstract][Full Text] [Related]
19. Circulating immune complexes and their possible relevance to other immunological parameters in Guatemalan onchocerciasis. Kawabata M; Izui S; Anan S; Kondo S; Fukumoto S; Flores GZ; Kobayakawa T Int Arch Allergy Appl Immunol; 1983; 72(2):128-33. PubMed ID: 6874107 [TBL] [Abstract][Full Text] [Related]
20. Comparison of antibody and cell-mediated immune responses of foals and adult horses after vaccination with live Mycobacterium bovis BCG. Sturgill TL; Giguère S; Berghaus LJ; Hurley DJ; Hondalus MK Vaccine; 2014 Mar; 32(12):1362-7. PubMed ID: 24486362 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]